Vitamin D Analogs May Break Pancreatic Cancer’s Barrier and Boost Chemo
TL;DR
A small randomized trial finds that adding the FDA-approved vitamin D analog paricalcitol to standard chemotherapy for metastatic pancreatic cancer safely remodels the tumor microenvironment by reducing fibroblast activation and increasing T cell presence, with higher response rates and one-year progression-free survival observed—especially in tumors with high vitamin D receptor expression—suggesting biomarker-guided potential and the need for larger trials.
Topics:top-newshealth#fibroblasts#health#pancreatic-cancer#paricalcitol#tumor-microenvironment#vitamin-d-receptor
- Vitamin D Drug Shows Surprising Promise Against One of the Deadliest Cancers SciTechDaily
- Does Revolution Medicines’ pancreatic cancer drug have even greater potential? statnews.com
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes The Cancer Letter
- Landmark pancreatic cancer treatment paves way for targeting other tricky tumors Scientific American
- Promising new treatment for pancreatic cancer doubles survival rates PBS
Want the full story? Read the original reporting
Read on SciTechDaily